Tvardi Therapeutics, Inc. 8K

Tvardi Therapeutics furnished an R&D presentation describing clinical and preclinical progress of STAT3 inhibitors TTI-101 and TTI-109, with TTI-109 advancing toward a Phase 2 ulcerative colitis program and TTI-101 in ongoing liver cancer studies.

The Form 8-K includes Tvardi Therapeutics’ July 2026 investor presentation (Exhibit 99.2), in which the company provides an extensive R&D and clinical update on its STAT3 inhibitor programs, highlighting Phase 1 data for prodrug TTI-109 in healthy volunteers, detailing its pharmacokinetics, safety, and immune-modulatory profile relative to parent compound TTI-101, and positioning TTI-109 for a planned ulcerative colitis Phase 2 trial while also summarizing ongoing Phase 1b/2 REVERT liver cancer and prior IPF data for TTI-101 and outlining anticipated IND and trial initiation milestones in 2026–2027.

Filing Facts

CIK

1346830

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-088461

Alert Tier

5